InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.085 -0.035 (-29.17%)+
Announcement
Release
17 Feb 2026 7:47PM
Price at Release
$0.120
Full Release
download
Summary
BCAL Diagnostics Limited released its half-yearly report for the period ending 31 December 2025. The company reported a revenue of $1,272,617 from continuing operations, marking an 8% decrease from the previous period. The loss from operations after tax attributable to members was $3,917,411, a 2% improvement compared to the previous year. The report highlighted no control was gained or lost over any entities during the period, and no dividends were proposed. The company is not involved in any joint ventures or associated entities and is not a foreign entity. The report was reviewed by Pitcher Partners, who confirmed no contraventions of auditor independence requirements or ethical codes. However, there is a noted material uncertainty about the Group's ability to continue as a going concern due to the incurred net loss and the need for additional funding.
Key Points
  • Half-yearly report ended 31 December 2025.
  • Revenue from continuing operations was $1,272,617, down 8%.
  • Net loss from operations after tax was $3,917,411, a 2% improvement.
  • No dividends proposed or paid.
  • No changes in control over entities.
  • No joint ventures or associates.
  • Auditor's review highlighted no contraventions.
  • Material uncertainty about going concern due to financial losses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.